Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker

Live webcast with members of the Autonomix management team, on Thursday, April 11^th at 12:00 PM ET

THE WOODLANDS, TX, April 08, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker event on Thursday, April 11, 2024 at 12:00 PM ET.

As part of the roundtable event, members of the Autonomix management team including Lori Bisson, Chief Executive Officer, Walter Klemp, Executive Chairman, Dr. Robert Schwartz, Chief Medical Officer, Trent Smith, Chief Financial Officer, Jennifer Cook, Chief Business Officer, and Marco Bedoya, Director of Product Development, will provide introductions and describe the important role they each play in achieving the Company’s common goal. Additionally, interested parties will have the opportunity to submit questions live. Management will answer as many questions as possible during the event.

A live video webcast of the event will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com